
News|Articles|September 26, 2023
How to mitigate risk for biologics during fill/finish manufacturing
Author(s)Emergent
As more biologics move through research and development, the demand for specialized aseptic fill/finish services has steadily climbed. Aseptic processing with the highest degree of sterility assurance, filling accuracy and quality is critical for high-value, small-batch therapies. Anything less impacts regulatory compliance, project timelines and—most importantly—patient safety. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Next-Generation Modalities Drive New Antibody Discovery
2
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
3
European Approval of Donidalorsen Expands RNA-Targeted Prevention Strategies for HAE
4
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
5